{"id":"W2403654892","doi":"10.1016/j.jtho.2016.05.008","title":"The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Pfizer Canada; Chugai Pharmaceutical; Eisai; National Comprehensive Cancer Network; Ariad Pharmaceuticals; Genentech; AstraZeneca Canada; EMD Serono; International Association for the Study of Lung Cancer; Gilead Sciences; GlaxoSmithKline; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Osimertinib; Epidermal growth factor receptor; Oncology; Internal medicine; Erlotinib; Targeted therapy; Tyrosine kinase; Cancer; Receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001302874,0.0002397993,0.001139538,0.0002763954,0.000109916,0.00001848722,0.0002529391,0.0001301849,0.00003241708],"category_scores_gemma":[0.00006837044,0.0001189122,0.0003128029,0.0001782299,0.00004434832,0.000042229,0.00006026575,0.000312728,6.014873e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007290891,"about_ca_system_score_gemma":0.00244913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003222516,"about_ca_topic_score_gemma":0.0003509795,"domain_scores_codex":[0.997203,0.0002942214,0.001524367,0.0002062484,0.0004942234,0.0002779769],"domain_scores_gemma":[0.9927451,0.00204539,0.004118617,0.0001865945,0.0008378815,0.00006640367],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001294539,0.001254708,0.000952674,0.003704236,0.01130978,0.0001073577,0.002123248,0.0009761073,0.000003164729,0.00003476341,0.004790282,0.9734491],"study_design_scores_gemma":[0.0155245,0.006369264,0.003684846,0.05891242,0.04890912,0.00005250262,0.01148889,0.0007317832,0.0000905084,0.00004681201,0.8537201,0.000469209],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003583349,0.9835849,0.0002820756,0.002930363,0.002499074,0.005433189,0.0004692222,0.000003874788,0.001213983],"genre_scores_gemma":[0.004120843,0.991433,0.000686978,0.00005471497,0.0002312245,0.000739895,0.00001978753,0.0000326213,0.00268098],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9729799,"threshold_uncertainty_score":0.9965199,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03320840595427421,"score_gpt":0.4896282325833793,"score_spread":0.4564198266291051,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}